NASDAQ: DTILPrecision Biosciences Inc Stock
$5.64+0.41 (+7.84%)
Updated Apr 30, 2025
DTIL Price
$5.64
Fair Value Price
N/A
Market Cap
$59.12M
52 Week Low
$3.61
52 Week High
$13.44
P/E
5.37x
P/B
1.05x
P/S
0.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$68.70M
Earnings
$7.17M
Gross Margin
100%
Operating Margin
13.03%
Profit Margin
10.4%
Debt to Equity
1.42
Operating Cash Flow
-$58M
Beta
1.3
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
DTIL Overview
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DTIL's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DTIL
Ranked#414 of 462
Ranked#414 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important DTIL news, forecast changes, insider trades & much more!
DTIL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DTIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DTIL is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DTIL is good value based on its earnings relative to its share price (5.37x), compared to the US market average (29.18x)
P/E vs Market Valuation
DTIL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DTIL due diligence checks available for Premium users.
Valuation
DTIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.37x
Industry
-162.28x
Market
29.18x
DTIL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DTIL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DTIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.05x
Industry
4.45x
DTIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DTIL's financial health
Profit margin
Revenue
$638.0k
Net Income
-$17.7M
Profit Margin
-2,781.3%
DTIL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DTIL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$136.4M
Liabilities
$80.0M
Debt to equity
1.42
DTIL's short-term assets ($94.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DTIL's short-term assets ($94.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DTIL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DTIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.7M
Investing
-$97.0k
Financing
$5.9M
DTIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DTIL vs Biotech Stocks
Precision Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.